Roivant Sciences Ltd. (ROIV) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $30.20 (+0.60%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Douglas Tsao | H.C. Wainwright | $34.00 | +12.6% |
| Dec 15, 2025 | David Risinger | Leerink Partners | $32.00 | +6.0% |
| Nov 14, 2025 | Yastin Suneja | Guggenheim | $25.00 | -17.2% |
| Nov 11, 2025 | David Risinger | Leerink Partners | $29.00 | -4.0% |
| Oct 21, 2024 | David Risinger | Leerink Partners | $17.00 | -43.7% |
| Sep 19, 2024 | Corinne Jenkins | Goldman Sachs | $17.00 | -43.7% |
| Sep 11, 2024 | Chi Fong | Bank of America Securities | $12.50 | -58.6% |
| May 31, 2024 | Allison Bratzel | Piper Sandler | $20.00 | -33.8% |
| Apr 3, 2024 | Douglas Tsao | H.C. Wainwright | $18.00 | -40.4% |
| Apr 3, 2024 | Neena Bitritto-Garg | Deutsche Bank | $15.00 | -50.3% |
| Apr 2, 2024 | Corinne Jenkins | Goldman Sachs | $18.00 | -40.4% |
| Mar 13, 2024 | Corinne Jenkins | Goldman Sachs | $16.00 | -47.0% |
Top Analysts Covering ROIV
ROIV vs Sector & Market
| Metric | ROIV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +22.8% | +11475.0% | +17.1% |
| P/E Ratio | -23.91 | 3.93 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3M | $3M | $3M | 5 |
| 2026-09-30 | $3M | $3M | $3M | 2 |
| 2026-12-31 | $19M | $19M | $19M | 2 |
| 2027-03-31 | $28M | $28M | $28M | 2 |
| 2027-06-30 | $33M | $33M | $33M | 2 |
| 2027-09-30 | $63M | $63M | $63M | 2 |
| 2027-12-31 | $115M | $115M | $115M | 2 |
| 2028-03-31 | $155M | $155M | $155M | 1 |
| 2029-03-31 | $1.69B | $1.69B | $1.69B | 6 |
| 2030-03-31 | $323M | $2.92B | $10.74B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.36 | $-0.29 | $-0.22 | 2 |
| 2026-09-30 | $-0.32 | $-0.32 | $-0.32 | 1 |
| 2026-12-31 | $-0.22 | $-0.22 | $-0.22 | 1 |
| 2027-03-31 | $-0.30 | $-0.30 | $-0.30 | 1 |
| 2027-06-30 | $-0.29 | $-0.29 | $-0.29 | 1 |
| 2027-09-30 | $-0.28 | $-0.28 | $-0.28 | 1 |
| 2027-12-31 | $-0.23 | $-0.23 | $-0.23 | 1 |
| 2028-03-31 | $-0.21 | $-0.21 | $-0.21 | 1 |
| 2029-03-31 | $-3.08 | $0.22 | $3.22 | 5 |
| 2030-03-31 | $-0.17 | $1.05 | $4.72 | 1 |
Frequently Asked Questions
What is the analyst consensus for ROIV?
The consensus among 9 analysts covering Roivant Sciences Ltd. (ROIV) is Buy with an average price target of $31.50.
What is the highest price target for ROIV?
The highest price target for ROIV is $34.00, set by Douglas Tsao at H.C. Wainwright on 2026-03-04.
What is the lowest price target for ROIV?
The lowest price target for ROIV is $12.50, set by Chi Fong at Bank of America Securities on 2024-09-11.
How many analysts cover ROIV?
9 analysts have issued ratings for Roivant Sciences Ltd. in the past 12 months.
Is ROIV a buy or sell right now?
Based on 9 analyst ratings, ROIV has a consensus rating of Buy (2.00/5) with a +22.8% upside to the consensus target of $31.50.
What are the earnings estimates for ROIV?
Analysts estimate ROIV will report EPS of $-0.29 for the period ending 2026-06-30, with revenue estimated at $3M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.